To understand how to get sermorelin prescribed, start with the part that matters most: a clinician has to decide that it fits. The usual route is a sermorelin-specific medical intake, review by a provider licensed in the state where you are, lab work if needed, and a prescription sent to a licensed compounding pharmacy. A responsible service can also say no.

Sermorelin is a growth-hormone-releasing hormone analog, meaning a lab-made version of a signal the brain uses to ask the pituitary gland for growth hormone. It isn't growth hormone itself.

How to get sermorelin prescribed in four steps

1. Complete the sermorelin intake. The form should ask about symptoms, goals, age, medical conditions, medicines, supplements, and past hormone or pituitary care. A generic wellness form isn't enough.

2. Wait for clinical review. The provider may approve, decline, or ask a follow-up question. That decision should happen before medication is dispensed.

3. Complete lab work if requested. The provider decides whether existing results are useful or new testing is needed. A lab value is evidence, not a password that unlocks a prescription.

4. If prescribed, the pharmacy fills it. A licensed U.S. compounding pharmacy prepares the medication for the individual prescription and supplies the directions. Follow-up lets the provider review response, side effects and whether continuing makes sense.

The guide to what to expect from a first visit explains the intake in more depth. At Promise, a licensed provider reviews every request, and not everyone qualifies.

What the provider is looking for

The provider is answering two questions: does the request make medical sense, and could sermorelin be unsafe for this person?

Age is context, not a diagnosis. Growth-hormone output changes as people get older, but age alone doesn't prove a hormone disorder. Lower energy or changes in recovery and body composition are also nonspecific; sleep problems, thyroid disease and anemia can look similar.

History often matters more. Prior pituitary disease, surgery or radiation near the brain, a serious head injury, or childhood growth-hormone deficiency may point toward a formal endocrine evaluation. A 2021 clinical review emphasized those risk factors and warned against diagnosing adult growth-hormone deficiency from vague symptoms alone (Tritos and Biller, Reviews in Endocrine and Metabolic Disorders).

A provider also needs the full medication and supplement list because other treatments and health conditions can change both lab results and the safety discussion.

Why IGF-1 helps but does not decide

A provider may look at IGF-1, or insulin-like growth factor 1, a blood marker made mainly by the liver after a growth-hormone signal. It gives a steadier snapshot than a random growth-hormone measurement because growth hormone rises and falls in pulses.

Still, IGF-1 isn't a stand-alone yes-or-no test. The same review found that it can miss some people and wrongly flag others. When true adult growth-hormone deficiency is suspected, a stimulation test—measuring the body's response after a medical trigger—is usually needed. That is an endocrinology question, not something an online intake can diagnose from one number.

A published review describes sermorelin as a 29-amino-acid peptide that stimulates the pituitary and summarizes its older use in growth-hormone testing and children with growth failure (Prakash and Goa, BioDrugs). It does not establish broad outcomes for healthy adults seeking sleep, recovery or body-composition changes.

What can disqualify someone or pause the decision

There is no checklist that guarantees approval. These issues are most likely to stop the process or require a different clinician first:

  • Active cancer. The Endocrine Society's adult growth-hormone guideline treats active malignancy as a contraindication to growth-hormone treatment (Molitch et al., Journal of Clinical Endocrinology & Metabolism). Sermorelin isn't growth hormone, but it is meant to stimulate the same system, so an active cancer is a serious reason to decline.
  • Pregnancy or breastfeeding. The safety evidence is not adequate for routine use in these settings, so a provider may decline or defer.
  • An unexplained pituitary problem. A known mass, prior surgery, new severe headaches or vision changes may call for specialist evaluation rather than a routine telehealth prescription.
  • Unstable health conditions or an incomplete medication history. Sometimes another issue or missing record needs attention first.

A past cancer diagnosis is different from active cancer. An international consensus found that growth-hormone treatment may be considered for some adult survivors in remission after an individual risk-benefit review (Boguszewski et al., European Journal of Endocrinology). For sermorelin, that history may lead to a decline, specialist clearance, or a longer conversation.

Why the state license and pharmacy record matter

A telehealth provider is practicing where the patient is located. Federal guidance explains that state rules vary and that a clinician needs a legal route to practice there, such as a full license, registration or compact privilege (Telehealth.HHS.gov). The state board can hold that clinician accountable. Checking a telehealth clinician's license takes the guesswork out of the claim.

The pharmacy should be identifiable too. A licensed pharmacy creates a record of who prepared and dispensed the medication. A grey-market vial has no accountable prescriber or pharmacy.

Sermorelin has an unusual regulatory history. No FDA-approved sermorelin product is currently marketed: Geref was approved in 1990 and 1997, and both approvals were withdrawn in 2009. FDA later determined that the products were not withdrawn for safety or effectiveness (Federal Register, March 4, 2013). The sermorelin dispensed here is a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

As of September 6, 2026, the day this article was written, the most relevant recent FDA action was a June 8, 2026, warning letter to a telehealth company. FDA objected to claims that compounded medicines and compounding pharmacies carried agency approval. The letter concerned semaglutide and tirzepatide, not sermorelin, but the lesson carries over: clear services say who prescribes, who compounds and what regulatory status the formulation has.

If sermorelin is not the best fit

A provider may decide that specialist testing should come first or discuss another option. CJC-1295 and ipamorelin act through two growth-hormone signaling routes and are not interchangeable with sermorelin. The choice belongs in the clinical review, not in a self-selected stack.

The sermorelin product page explains the primary option, while the sermorelin side-effects guide covers questions worth raising before a decision. For what a recurring plan's monthly price actually covers, and who is accountable for it, see sermorelin cost.

What to have ready for the visit

A current list of medicines and supplements helps the provider see the whole picture. So do recent labs, details of any cancer or pituitary care, and a clear description of what prompted the request.

The goal isn't to make the intake look approvable. It is to give the clinician enough accurate information to make a safe call and explain it.